Quantum Cyber N.V. quarterly report, Q1 FY2026

Business Context and Reporting Period

Company: Quantum Cyber N.V. (formerly Mainz Biomed N.V.)
Filing Type: Form 10-Q
Period: Quarter ended March 31, 2026
Status: Smaller Reporting Company; Emerging Growth Company
Overview: The Company is domiciled in the Netherlands with operations primarily in Germany. Historically focused on in-vitro diagnostic (IVD) tests for cancer detection, the Board decided in February 2026 to exit the colorectal cancer screening business (ColoAlert and NextGen lines) to focus on pancreatic cancer screening and explore post-quantum cybersecurity opportunities. Consequently, the colorectal business is reported as discontinued operations. The Company changed its name and ticker symbol (QUCY) in April 2026.

Key Financial Metrics

Metric Q1 2026 Q1 2025
Revenue (Continuing Ops) $0 $0
Revenue (Discontinued Ops) $170,105 $152,405
Net Loss $(5,081,982) $(5,002,891)
Loss from Continuing Ops $(2,485,595) $(2,767,457)
Loss from Discontinued Ops $(2,596,387) $(2,235,434)
Cash and Equivalents (End of Period) $4,752,966 $1,835,425
Total Assets $7,717,957 $5,327,396
Total Liabilities $3,128,665 $4,685,796
Shareholders' Equity $4,589,292 $641,600
Accumulated Deficit $(109,984,357) $(104,902,375)

Liquidity: Cash increased significantly to approximately $4.75 million due to financing activities. The Company reports a working capital deficit of approximately $3.5 million (excluding assets/liabilities held for sale) and faces substantial doubt regarding its ability to continue as a going concern without additional financing.

Material Changes vs. Prior Period

  • Capital Structure: Issued 3,000,000 Series A, B, and C preferred shares for $3 million (First Closing) and recorded a $3 million advance for Series D and E preferred shares (Second Closing) as "preferred shares payable." Issued 1,735,194 ordinary shares for net proceeds of $2.1 million.
  • Operating Expenses: Total operating expenses for continuing operations decreased by 10% to $2.46 million. Sales and marketing expenses dropped 76% due to the exit of the colorectal business. General and administrative expenses increased 42% primarily due to $800,000 in share-based compensation.
  • Discontinued Operations: The Company recorded a loss of $2.60 million from discontinued operations, driven by the wind-down of the German subsidiary, severance costs, and an impairment loss of $538,393 on property and equipment.
  • Cash Flow: Net cash provided by financing activities was $7.27 million, a reversal from a $357,000 outflow in the prior year, driven by the preferred and ordinary share issuances.

Outlook, Risks, and Unusual Items

  • Going Concern: Management states substantial doubt exists regarding the Company's ability to continue as a going concern for the next 12 months due to recurring losses, negative working capital, and lack of established revenue sources. Future operations depend on successful capital raises.
  • Strategic Pivot: The Company is transitioning from colorectal cancer diagnostics to pancreatic cancer screening and post-quantum cybersecurity. In May 2026 (subsequent event), the Company entered an IP license agreement with BP United Inc. for $5 million cash and 20 million shares to access cyber/drone technology.
  • Asset Sales: Subsequent to the quarter end, the Company sold ColoAlert assets (March 2026) and NextGen IP (April 2026) for a total of approximately $1.6 million, settling related debts and liabilities.
  • Internal Controls: The Company identified a material weakness in internal controls over financial reporting, citing insufficient written policies, lack of documentation, and inadequate segregation of duties.
  • Legal Proceedings: A dispute with Boustead Securities regarding financial services compensation is pending in the Supreme Court of New York; no claims are currently pending against the Company in this matter.

Investor Verification Checklist

  • Capital Sufficiency: Verify the timeline and certainty of the "Second Closing" of the preferred stock offering and the ability to raise further capital given the going concern warning.
  • Discontinued Operations Settlement: Confirm the final net proceeds from the sale of ColoAlert and NextGen assets and the full settlement of associated liabilities (leases, severance).
  • BP United Transaction: Review the terms of the May 2026 IP license agreement, specifically the conditions precedent for the $5 million cash payment and the issuance of 20 million shares.
  • Internal Control Remediation: Assess the plan and timeline for remedying the material weakness in internal controls over financial reporting.
  • Share Dilution: Monitor the impact of the authorized share increase to 900 million and the issuance of shares for strategic advisors and the BP United deal on existing shareholder value.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.